The global conjunctivitis market size is expected to be worth US$ 1,825.8 Million in 2022. The market is expected to reach US$ 3,208.7 Million by 2032, growing at a 5.8% CAGR from 2022 to 2032.
The factors responsible for growth are:
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.
| Report Attribute | Details |
|---|---|
| Conjunctivitis Market Value (2022) | US$ 1825.8 Million |
| Conjunctivitis Market Anticipated Value (2032) | US$ 3208.7 Million |
| Conjunctivitis Projected Growth Rate (2022 to 2032) | 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Due to increased awareness, significant increases in healthcare spending, and a rising frequency of ocular allergies in the region, the Asia Pacific conjunctivitis market is anticipated to develop at the highest CAGR during the forecast period. Conjunctivitis is quite prevalent in nations like India. For instance, the state of Tamil Nadu reported a viral conjunctivitis issue among students and workers at schools. Clinical Epidemiology and Global Health, for instance, estimated that 12.22% of Indians suffer from ocular allergies. The male segment is projected to have a higher prevalence (13.44%) than females (10.71%). During the projected period, these trends are anticipated to support market expansion in the region.
The emergence of cost-effective generic drugs is probably going to severely impede market expansion. Due to an increase in the frequency of infections, poor hygienic conditions in developing nations, and protracted deliveries in several of the region's countries, the Asia Pacific region is anticipated to have the third-largest share. In addition, it is anticipated that the expanding medical tourism sector in nations like Malaysia, China, and India would increase demand for treatment. Over the anticipated time, these factors boost market expansion in the region.
The market share of the other regions, including Latin America, the Middle East, and Africa, was relatively smaller throughout the projection period. According to epidemiological research, for example, the incidence of ocular allergy in Mexico is estimated to be at 16.7%. Particularly noticeable in tropical or warm settings is this high frequency of ocular allergies.
Pharmaceutical companies are developing new options for treating conjunctivitis while evaluating how well they relieve ocular irritation. Large pharmaceutical companies are funding all of this research. These factors are promoting the expansion of the global market for conjunctivitis treatment. Due to the increased illness awareness and increased global healthcare spending, the conjunctivitis market is expected to alter over the forecast period, allowing medication producers to extend their share.
Companies and academics are striving to evaluate obstacles and look for possibilities that might have an impact on bacterial conjunctivitis research and development. The focus of the currently being developed therapies is on cutting-edge methods to cure or ameliorate the state of illness. However, it is anticipated that these regions are likely to see development in the future owing to the expanded market presence of well-known brands and the high prevalence of ocular allergies there.
Companies like Sun Pharmaceuticals and Alembic Pharmaceuticals Limited are expanding their market share globally by concentrating on product approvals and the introduction of generic versions of already available medications. Moreover, startups like Ocular Therapeutix, Inc. and Eton Pharmaceutical are also working to secure regulatory clearances for their pipeline candidates, which is anticipated to help them boost their profits during the projection period.
The global market share of conjunctivitis is predicted to rise owing to fast-growing technological advancement, expanding geriatric population, growing disease prevalence, and surging demand for effective drug types. These are all responsible for fueling the growth of the global market of this industry.
Principal Consultant
The global conjunctivitis market is motivated by increasing air pollution in the majority of cities across the world. The National Center for Biotechnology Information (NCBI) published a research study in 2016 that the critical reasons for the occurrence and worsening of allergic conjunctivitis are ambient air pollution and weather changes. This is accredited to the conjunctiva being sensitive to environmental particles coupled with direct contact of the conjunctiva with the external environment. Therefore, an increase in air pollution promotes the growth of the global conjunctivitis treatment market.
Increased awareness about allergic conjunctivitis amongst the medical community, patients, and individuals associated with patients is one of the key market-driving factors responsible for the growth of the conjunctivitis market. Developing lifestyles and overall growth in the number of patients suffering from allergic conjunctivitis are primary factors boosting the growth of the market. Many biopharmaceutical companies plan to invest in research and development initiatives to develop new drugs and therapies for treating ocular disorders. Recently, the increasing awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The North American market is anticipated to dominate the global conjunctivitis market share over the forecast period. FMI analysts predict that by 2022, the regional conjunctivitis market will bloom with a revenue share of over 27%.
North America is the biggest market due to the increasing prevalence of allergic conjunctivitis in this region. An estimate says that nearly 70 to 80 million Americans suffer from ocular allergies. There is greater awareness of ophthalmic allergies in the region. This, coupled with the existence of majority players, which leads to novel and advanced drug launches, and the robust spread of this disease, are factors attributing to the market's growth. A country like the USA has a major presence of positive reimbursement policies, and this is the key reason for this region's dominance in this market.
Europe is accountable for a 22% market share in the global conjunctivitis market. The emergence as the second-largest regional market owing to the growing potential patient population in the region along with the growing use of sophisticated drugs. For example, based on the British Journal of Ophthalmology, in the United Kingdom, seasonal allergic conjunctivitis is a widespread and one of the mild forms of allergic conjunctivitis. It accounts for 25 to 50 percent of all ocular allergy cases, and it is predicted to affect between 10 to 15 percent of the population in the United Kingdom.
Some of the key players in the conjunctivitis market are Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Atopix Therapeutics Ltd., Novartis AG, Ocular Therapeutix, Inc., Bausch & Lomb Inc., Akorn Incorporated., Auven Therapeutics, Sirion Therapeutics, Inc., Sun Pharma Advanced Research Company Ltd., C Boehringer Ingelheim International GmbH., IBA Vision Ophthalmics, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd.
| Who | Bausch & Lomb Inc. |
|---|---|
| When | May 2022 |
| Strategic Move | Bausch + Lomb Corporation - a leading eye health company launched as a publicly traded company focused on protecting and improving the gift of sight for millions of people around the globe when it started trading under the BLCO symbol on the New York Stock Exchange and Toronto Stock Exchange. |
| Who | Sanofi-Aventis |
|---|---|
| When | August 2022 |
| Strategic Move | Sanofi and Innovent Biologics collaborated to bring innovative medicines to patients in China with difficult-to-treat cancers. Both companies are committed to accelerating the development and commercialization of two Sanofi key clinical-stage oncology assets. Moreover, besides the agreement and collaboration, Sanofi will invest €300 million in Innovent through the subscription of novel common shares. |
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The growth outlook for the conjunctivitis market is predicted to advance at a CAGR of 5.8% from 2022 to 2032.
The North American region is anticipated to lead the conjunctivitis market during the forecast period.
The conjunctivitis market is likely to hold a valuation of US$ 3208.7 million by 2032.
1. Executive Summary | Conjunctivitis Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type Of Allergy
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type Of Allergy, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type Of Allergy, 2022 to 2032
5.3.1. Acute Allergic Conjunctivitis
5.3.2. Chronic Allergic Conjunctivitis
5.4. Y-o-Y Growth Trend Analysis By Type Of Allergy, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Type Of Allergy, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2022 to 2032
6.3.1. Antihistamines
6.3.2. Vasoconstrictors
6.3.3. Mast Cell Stabilizers
6.3.4. Non-Steroidal Anti-Inflammatory Drugs
6.3.5. Corticosteroids
6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Drug Type, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Type Of Allergy
8.2.3. By Drug Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type Of Allergy
8.3.3. By Drug Type
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type Of Allergy
9.2.3. By Drug Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type Of Allergy
9.3.3. By Drug Type
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Type Of Allergy
10.2.3. By Drug Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type Of Allergy
10.3.3. By Drug Type
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. India
11.2.1.5. Malaysia
11.2.1.6. Singapore
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Type Of Allergy
11.2.3. By Drug Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type Of Allergy
11.3.3. By Drug Type
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Type Of Allergy
12.2.3. By Drug Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type Of Allergy
12.3.3. By Drug Type
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Type Of Allergy
13.1.2.2. By Drug Type
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Type Of Allergy
13.2.2.2. By Drug Type
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Type Of Allergy
13.3.2.2. By Drug Type
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Type Of Allergy
13.4.2.2. By Drug Type
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Type Of Allergy
13.5.2.2. By Drug Type
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Type Of Allergy
13.6.2.2. By Drug Type
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Type Of Allergy
13.7.2.2. By Drug Type
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Type Of Allergy
13.8.2.2. By Drug Type
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Type Of Allergy
13.9.2.2. By Drug Type
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Type Of Allergy
13.10.2.2. By Drug Type
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Type Of Allergy
13.11.2.2. By Drug Type
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Type Of Allergy
13.12.2.2. By Drug Type
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Type Of Allergy
13.13.2.2. By Drug Type
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Type Of Allergy
13.14.2.2. By Drug Type
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Type Of Allergy
13.15.2.2. By Drug Type
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Type Of Allergy
13.16.2.2. By Drug Type
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Type Of Allergy
13.17.2.2. By Drug Type
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Type Of Allergy
13.18.2.2. By Drug Type
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Type Of Allergy
13.19.2.2. By Drug Type
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type Of Allergy
14.3.3. By Drug Type
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Boehringer Ingelheim GmbH
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Allergan Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Sanofi-Aventis
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Novartis AG
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Bausch & Lomb Inc
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. CIBA Vision Ophthalmics
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Pfizer Inc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Merck & Co., Inc
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Santen Pharmaceuticals Co. Ltd
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Alcon
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Conjunctivitis Market
